Table 4 Laplace regression models with years to first 10% of total mortality as outcome for patients aged ≥45 years with diagnoses of AF and diabetes mellitus ( n = 2,413) attending the 75 PHCCs between January 1st2001 and December 31st2007, stratified by age: 45–79 years (n = 1,704) and 80–104 years (n = 709)
Patients aged <80 years | Patients aged ≥80 years | All patients | |
|---|---|---|---|
Full model | Full model | Full model | |
HR (95% CI) | HR (95% CI) | HR (95% CI) | |
Antithrombotic drugs | |||
Antiplatelets vs. no treatment | 0.81 (-1.24; 2.87) | 1.78 (1.04; 2.52) | 1.02 (-0.34; 2.39) |
Anticoagulants vs. no treatment | 2.70 (0.04; 5.37) | 1.22 (-0.06; 2.51) | 2.20 (0.79; 3.62) |
Anticoagulants vs. antiplatelets | 2.31 (0.84; 3.79) | 0.23 (-1.10; 1.55) | 1.21 (-0.03; 2.45) |
Digitalis | 1.02 (-0.26; 2.30) | 0.25 (-2.35; 2.85) | 0.58 (-0.28; 1.45) |
Loop diuretics | -2.44 (-3.79; -1.08) | 0.69 (-0.89; 2.26) | -1.22 (-2.79; 0.34) |
Thiazides | 0.18 (-1.34; 1.70) | 1.09 (0.10; 2.07) | 0.35 (-0.56; 1.24) |
Aldosterone antagonists | -0.17 (-1.23; 0.88) | -0.17 (-0.89; 0.56) | -0.07 (-0.90; 0.76) |
Beta blockers | 1.28 (-0.13; 2.69) | 0.29 (-0.47; 1.06) | 1.18 (0.32; 2.04) |
RAS-blocking agents | -0.18 (-1.40; 1.04) | -0.19 (-0.74 (0.36) | 0.23 (-0.57; 1.02) |
Calcium receptor-blocking agents | -0.02 (-1.20; 1.16) | -0.07 (-0.86; 0.72) | -0.54 (-1.61; 0.53) |
Statins | 2.11 (0.88; 3.35) | 0.38 (-1.37; 2.14) | 1.24 (0.38; 2.10) |